OTCMKTS:IPHYF - Innate Pharma Stock Price, News, & Analysis

Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France.

Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions

What is Innate Pharma's stock symbol?

Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."

What is the consensus analysts' recommendation for Innate Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innate Pharma.

Who are some of Innate Pharma's key competitors?

Some companies that are related to Innate Pharma include Vanda Pharmaceuticals (VNDA), Esperion Therapeutics (ESPR), Intra-Cellular Therapies (ITCI), Omeros (OMER), Retrophin (RTRX), Alder Biopharmaceuticals (ALDR), Zai Lab (ZLAB), Lexicon Pharmaceuticals (LXRX), Viking Therapeutics (VKTX), Eagle Pharmaceuticals (EGRX), Athenex (ATNX), Karyopharm Therapeutics (KPTI), CannTrust (CNTTF), Apellis Pharmaceuticals (APLS) and Rhythm Pharmaceuticals (RYTM).

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the folowing people:

• Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 57)
• Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 60)
• Mr. Yannis Morel, Exec. VP-Products Portfolio Strategy & Bus. Devel. & Member of Exec. Board (Age 45)
• Dr. François Romagné Ph.D., Co Founder and Member of the Scientific Advisory Board (Age 54)
• Ms. Laure-Hélène Mercier, Exec. VP & CFO (Age 40)

How do I buy shares of Innate Pharma?

Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innate Pharma's stock price today?

One share of IPHYF stock can currently be purchased for approximately $5.34.

How big of a company is Innate Pharma?

Innate Pharma has a market capitalization of $303.55 million and generates $49.74 million in revenue each year. The company earns $-54,680,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Innate Pharma employs 194 workers across the globe.

What is Innate Pharma's official website?

The official website for Innate Pharma is http://www.innate-pharma.com.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]